IRISanRaf

PICCONI, BARBARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.646
AS - Asia 961
EU - Europa 301
Continente sconosciuto - Info sul continente non disponibili 67
OC - Oceania 14
AF - Africa 9
SA - Sud America 5
Totale 4.003
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.266
TR - Turchia 809
CA - Canada 380
IT - Italia 122
CN - Cina 102
EU - Europa 67
IE - Irlanda 43
GB - Regno Unito 39
DE - Germania 26
IN - India 18
FR - Francia 11
RO - Romania 10
RU - Federazione Russa 10
FI - Finlandia 9
AU - Australia 8
DK - Danimarca 6
JP - Giappone 6
NL - Olanda 6
NZ - Nuova Zelanda 6
SC - Seychelles 6
ES - Italia 5
TW - Taiwan 5
UA - Ucraina 5
BE - Belgio 3
BR - Brasile 3
CL - Cile 2
EG - Egitto 2
ID - Indonesia 2
IL - Israele 2
IR - Iran 2
LK - Sri Lanka 2
PH - Filippine 2
PS - Palestinian Territory 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BG - Bulgaria 1
CH - Svizzera 1
GR - Grecia 1
KE - Kenya 1
KR - Corea 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
OM - Oman 1
PT - Portogallo 1
SA - Arabia Saudita 1
SE - Svezia 1
SG - Singapore 1
Totale 4.003
Salva come PNG Salva come JPEG
Città #
Kocaeli 807
San Mateo 688
Toronto 373
Wilmington 202
Houston 180
Chandler 159
Lawrence 139
Princeton 139
Fairfield 84
Beijing 79
Ashburn 77
Woodbridge 48
Seattle 46
Redwood City 34
Cambridge 22
Dublin 21
Falls Church 19
Los Angeles 19
Rome 16
Brooklyn 10
Constanta 10
Helsinki 9
Pune 9
Chicago 6
Bristol 5
Padova 5
Saint Louis 5
Genoa 4
Redmond 4
Shanghai 4
Taipei 4
Tokyo 4
Trento 4
Washington 4
Buffalo 3
Florence 3
Franz Josef 3
Kunming 3
Kyiv 3
London 3
Madrid 3
Opelousas 3
Boardman 2
Bolzano 2
Carasco 2
Hefei 2
Jakarta 2
Johnstown 2
Kemerovo 2
Kumar 2
Leicester 2
Manassas 2
Norwalk 2
Novokuznetsk 2
Ottawa 2
Palmerston North 2
Pesaro 2
Rockville 2
West Jordan 2
Airdrie 1
Ann Arbor 1
Apo 1
Auchterarder 1
Bangalore 1
Berkeley 1
Birkenhead 1
Bloomfield 1
Bordeaux 1
Brattvåg 1
Brentford 1
Brescia 1
Camberley 1
Cheboksary 1
Chippenham 1
Clatskanie 1
Clearwater 1
Collazzone 1
Colombo 1
Culver City 1
Daejeon 1
Dalry 1
Dhaka 1
Dompierre 1
Dudley 1
Dundee 1
Dunrobin 1
Farnborough 1
Ferrara 1
Frankfurt am Main 1
Freiberg 1
Geneva 1
Gurgaon 1
Hamilton 1
Hangzhou 1
Hanover 1
Hillsborough 1
Istanbul 1
Jinan 1
Karby 1
Kathmandu 1
Totale 3.338
Salva come PNG Salva come JPEG
Nome #
Direct and indirect pathways of basal ganglia: a critical reappraisal 155
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 100
A2A Adenosine Receptor Antagonism Enhances Synaptic and Motor Effects of Cocaine via CB1 Cannabinoid Receptor Activation 63
Acetyl-L-Carnitine selectively prevents post-ischemic LTP via a possible action on mitochondrial energy metabolism. 48
Synaptic dysfunction in Parkinson's disease 46
New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease 46
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. 44
Theta-burst stimulation and striatal plasticity in experimental parkinsonism 42
Differential effect of FHM2 mutation on synaptic plasticity in distinct hippocampal regions. 40
Role of tonically-active neurons in the control of striatal function: Cellular mechanisms and behavioral correlates 40
Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors 40
Dopaminergic control of synaptic plasticity in the dorsal striatum 39
NR2B-containing NMDA receptors promote the neurotoxic effects of 3-nitropropionic acid but not of rotenone in the striatum. 39
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. 39
NMDA receptor G1uN2D subunit participates to levodopa-induced dyskinesia pathophysiology 39
Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease. 38
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts 38
A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity 38
Tissue plasminogen activator is required for corticostriatal long-term potentiation 37
Dopamine drives binge-like consumption of a palatable food in experimental parkinsonism. 37
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities 37
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 37
Activation of metabotropic glutamate receptor subtype 1/protein kinase C/mitogen-activated protein kinase pathway is required for postischemic long-term potentiation in the striatum 37
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 37
Interaction between basal ganglia and limbic circuits in learning and memory processes 36
BDNF-TrkB signaling in striatopallidal neurons controls inhibition of locomotor behavior 36
Mechanisms underlying dopaminergic control of cortico-striatal synaptic transmission 36
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism 36
An abnormal striatal synaptic plasticity may account for the selective neuronal vulnerability in Huntington's disease 36
Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors 36
Dopamine denervation induces neurotensin immunoreactivity in GABA-parvalbumin striatal neurons 36
Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum 36
Corticostriatal synaptic plasticity alterations in the R6/1 transgenic mouse model of Huntington's disease 36
Environmental enrichment restores CA1 hippocampal LTP and reduces severity of seizures in epileptic mice 35
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 35
Neural networks and synaptic plasticity in Parkinson's disease: beyond motor deficits 35
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. 35
Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias 35
Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine 34
A synaptic mechanism underlying the behavioral abnormalities induced by manganese intoxication 34
Neuronal vulnerability following inhibition of mitochondrial complex II: a possible ionic mechanism for Huntington's disease. 34
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap 34
Striatum-hippocampus balance: From physiological behavior to interneuronal pathology 34
Motor Complications in Parkinson's Disease: Striatal Molecular and Electrophysiological Mechanisms of Dyskinesias 34
Ischemic-LTP in striatal spiny neurons of both direct and indirect pathway requires the activation of D1-like receptors and NO/soluble guanylate cyclase/cGMP transmission 34
Stimulation of D1/PKA/DARPP-32/PP-1 pathway is required for corticostriatal LTD and LTP 34
Protein phosphatase inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat hippocampal neurons 34
Rhes-mTORC1 interaction: A new possible therapeutic target in Parkinson's disease and L-dopa-induced dyskinesia? 33
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. 33
Epilepsy-induced abnormal striatal plasticity in Bassoon mutant mice. 33
Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice 33
New Synaptic and Molecular Targets for Neuroprotection in Parkinson's Disease 33
Early Synaptic Dysfunction in Parkinson's Disease: Insights From Animal Models 33
N-Methyl-D-aspartate (NMDA) Receptor Composition Modulates Dendritic Spine Morphology in Striatal Medium Spiny Neurons 33
Prenatal stress and hippocampal BDNF expression: a fading imperative 33
Motor learning and metaplasticity in striatal neurons: relevance for Parkinson's disease 32
Molecular mechanisms underlying levodopa-induced dyskinesia. 32
Dopamine-Dependent Long-Term Depression Is Expressed in Striatal Spiny Neurons of Both Direct and Indirect Pathways: Implications for Parkinson's Disease 32
The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D-2/A(2A) Receptor Interaction in the Striatum: Implications for Parkinson's Disease 32
A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance. 32
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias 31
Alpha-synuclein targets GluN2A NMDA receptor subunit causing striatal synaptic dysfunction and visuo-spatial memory alteration. 31
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia 31
Memantine alters striatal plasticity inducing a shift of synaptic responses toward long-term depression 31
Striatal spreading depolarization: possible implication in L-DOPA-induced dyskinetic like-behavior. 31
mTOR inhibitor rapamycin suppresses striatal post-ischemic LTP 31
Memantine reduces neuronal dysfunctions triggered by in vitro ischemia and 3-nitropropionic acid 31
Targeting Metabotropic Glutamate Receptors as a New Strategy Against Levodopa-Induced Dyskinesia in Parkinson's Disease? 31
Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. 31
Intermittent Theta-burst Stimulation Rescues Dopamine-Dependent Corticostriatal Synaptic Plasticity and Motor Behavior in Experimental Parkinsonism: Possible Role of Glial Activity 31
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease? 30
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia 30
NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients 30
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment 30
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission 30
Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. 30
Decreased NR2B subunit synaptic levels cause impaired long-term potentiation but not long-term depression. 29
Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease 29
Multiple mechanisms underlying the neuroprotective effects of antiepileptic drugs against in vitro ischemia 29
Lamotrigine and remacemide protect striatal neurons against in vitro ischemia: an electrophysiological study 29
Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. 29
Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine 29
Deficits of glutamate transmission in the striatum of experimental hemiballism. 29
Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction. 28
Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission 28
Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons 28
Is pharmacological neuroprotection dependent on reduced glutamate release? 28
Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity 28
Dopamine-mediated regulation of corticostriatal synaptic plasticity. 28
Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease 28
Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition. 28
Pathways of neurodegeneration and experimental models of basal ganglia disorders: downstream effects of mitochondrial inhibition. 28
Na+/Ca2+ exchanger maintains ionic homeostasis in the peri-infarct area. 28
The endocannabinoid system in Parkinson's disease. 28
Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit 28
Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism 28
Subthalamic nucleus lesion reverses motor abnormalities and striatal glutamatergic overactivity in experimental parkinsonism 27
NR2B subunit exerts a critical role in postischemic synaptic plasticity. 27
Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment 27
Unilateral dopamine denervation blocks corticostriatal LTP 27
Totale 3.550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.303
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.303
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20194 0 0 0 0 0 0 0 0 0 0 1 3
2019/2020497 8 28 2 2 45 81 12 19 57 52 102 89
2020/20211.362 89 58 33 11 44 92 70 22 35 48 807 53
2021/20221.349 11 369 372 1 9 12 89 139 36 279 11 21
2022/2023647 308 15 13 54 33 16 5 21 29 63 82 8
2023/2024265 0 2 17 127 26 17 15 37 3 21 0 0
Totale 4.247